KR102877857B1 - 치환된 크산틴 유도체 - Google Patents

치환된 크산틴 유도체

Info

Publication number
KR102877857B1
KR102877857B1 KR1020217021875A KR20217021875A KR102877857B1 KR 102877857 B1 KR102877857 B1 KR 102877857B1 KR 1020217021875 A KR1020217021875 A KR 1020217021875A KR 20217021875 A KR20217021875 A KR 20217021875A KR 102877857 B1 KR102877857 B1 KR 102877857B1
Authority
KR
South Korea
Prior art keywords
mmol
mixture
added
esi
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217021875A
Other languages
English (en)
Korean (ko)
Other versions
KR20210102955A (ko
Inventor
카이 게를라흐
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
하이드라 바이오사이언시스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하, 하이드라 바이오사이언시스, 엘엘씨 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20210102955A publication Critical patent/KR20210102955A/ko
Application granted granted Critical
Publication of KR102877857B1 publication Critical patent/KR102877857B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217021875A 2018-12-12 2019-12-10 치환된 크산틴 유도체 Active KR102877857B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18212060.0 2018-12-12
EP18212060 2018-12-12
PCT/EP2019/084375 WO2020120450A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (2)

Publication Number Publication Date
KR20210102955A KR20210102955A (ko) 2021-08-20
KR102877857B1 true KR102877857B1 (ko) 2025-10-29

Family

ID=64665184

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021875A Active KR102877857B1 (ko) 2018-12-12 2019-12-10 치환된 크산틴 유도체

Country Status (18)

Country Link
US (2) US11198696B2 (https=)
EP (1) EP3894410B1 (https=)
JP (1) JP7502299B2 (https=)
KR (1) KR102877857B1 (https=)
CN (1) CN113166151B (https=)
AU (1) AU2019396499B2 (https=)
BR (1) BR112021008316A2 (https=)
CL (1) CL2021001509A1 (https=)
DK (1) DK3894410T3 (https=)
EA (1) EA202191588A1 (https=)
ES (1) ES2964630T3 (https=)
HU (1) HUE064908T2 (https=)
IL (1) IL283768B2 (https=)
MX (1) MX2021007019A (https=)
PH (1) PH12021551345A1 (https=)
PL (1) PL3894410T3 (https=)
TW (1) TWI825243B (https=)
WO (1) WO2020120450A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok
WO2024164818A1 (zh) * 2023-02-08 2024-08-15 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107082782B (zh) 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法
WO2016023830A1 (en) 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
DK3652176T3 (da) * 2017-07-11 2022-01-17 Boehringer Ingelheim Int Substituerede xanthinderivater
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok

Also Published As

Publication number Publication date
IL283768A (en) 2021-07-29
IL283768B2 (en) 2024-05-01
HUE064908T2 (hu) 2024-04-28
US11198696B2 (en) 2021-12-14
DK3894410T3 (da) 2023-11-27
TWI825243B (zh) 2023-12-11
AU2019396499B2 (en) 2024-10-10
WO2020120450A1 (en) 2020-06-18
CA3119229A1 (en) 2020-06-18
CL2021001509A1 (es) 2021-12-17
KR20210102955A (ko) 2021-08-20
BR112021008316A2 (pt) 2021-08-03
CN113166151B (zh) 2023-12-01
EP3894410A1 (en) 2021-10-20
PH12021551345A1 (en) 2022-05-11
JP2022512373A (ja) 2022-02-03
CN113166151A (zh) 2021-07-23
US20200190093A1 (en) 2020-06-18
MX2021007019A (es) 2021-09-10
ES2964630T3 (es) 2024-04-08
EA202191588A1 (ru) 2021-10-18
PL3894410T3 (pl) 2024-03-18
US20220177479A1 (en) 2022-06-09
JP7502299B2 (ja) 2024-06-18
EP3894410B1 (en) 2023-10-11
IL283768B1 (en) 2024-01-01
AU2019396499A1 (en) 2021-05-27
TW202039495A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
CN113227068B (zh) Glp-1r激动剂及其用途
CN110461830B (zh) Jak1选择性抑制剂
CA2828478A1 (en) Serine/threonine kinase inhibitors
KR102877857B1 (ko) 치환된 크산틴 유도체
CN109526220B (zh) 用于治疗疼痛和疼痛相关的状况的四氢嘧啶并二氮杂䓬和四氢吡啶并二氮杂䓬化合物
CN106470985A (zh) 作为可溶性鸟苷酸环化酶激活剂的茚满和二氢吲哚衍生物及其用途
TW201925204A (zh) 稠合三環化合物
CN110997675A (zh) 新的取代的黄嘌呤衍生物
JP7408662B2 (ja) 置換キサンタン誘導体
TW201504227A (zh) 環狀胺基甲基嘧啶衍生物
WO2021115495A1 (zh) 一种小分子含硫杂环化合物
CN105793249B (zh) 用于治疗或预防精神病学和神经病学疾患的哌啶衍生物
CA3119229C (en) Substituted xanthine derivatives
EA043969B1 (ru) Замещенные ксантиновые производные
HK40110795A (zh) 稠环化合物
HK40109856A (zh) 稠环化合物
HK40110213A (zh) 稠环化合物
HK40110226A (zh) 稠环化合物
WO2024207945A1 (zh) 作为aak1抑制剂的氮杂环类化合物
KR20260043134A (ko) Sstr4의 작용제로서 (2s,5r)-5-(하이드록시메틸)모르폴린-2-카복스아미드
HK40041215B (zh) 稠环化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)